{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:33:32Z","timestamp":1791898412892,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Lambert Initiative for Cannabinoid Therapeutics"},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cannabis and its major constituents, \u0394<jats:sup>9<\/jats:sup>-tetrahydrocannabinol (THC) and cannabidiol (CBD), are being widely used to treat sleep disturbances. However, THC can cause acute cognitive and psychomotor impairment and there are concerns that driving and workplace safety might be compromised the day after evening use.\u00a0Here, we\u00a0examined possible \u2018next day\u2019 impairment following evening administration of a typical medicinal cannabis oil in adults with insomnia disorder, compared to matched placebo. This paper describes the secondary outcomes of a larger study investigating the effects of THC\/CBD on insomnia disorder.\u00a0Twenty adults [16 female; mean (SD) age, 46.1 (8.6) y] with physician-diagnosed insomnia who infrequently use cannabis completed two 24 h in-laboratory visits involving acute oral administration of combined 10 mg THC and 200 mg CBD (\u2018THC\/CBD\u2019) or placebo in a randomised, double-blind, crossover trial design. Outcome measures included \u2018next day\u2019 (\u22659 h post-treatment) performance on cognitive and psychomotor function tasks, simulated driving performance, subjective drug effects, and mood.\u00a0We found\u00a0no differences in \u2018next day\u2019 performance on 27 out of 28 tests of cognitive and psychomotor function and simulated driving performance relative to placebo. THC\/CBD produced a small decrease (-1.4%, <jats:italic>p<\/jats:italic>=.016, <jats:italic>d<\/jats:italic>=-0.6) in accuracy on the <jats:italic>Stroop-Colour Task<\/jats:italic> (easy\/congruent) but not the <jats:italic>Stroop-Word Task<\/jats:italic> (hard\/incongruent). THC\/CBD also produced a small increase (+8.6, <jats:italic>p<\/jats:italic>=.042, <jats:italic>d<\/jats:italic>=0.3) in self-ratings of <jats:italic>Sedated<\/jats:italic> at 10 h post-treatment, but with no accompanying changes in subjective ratings of <jats:italic>Alert<\/jats:italic> or <jats:italic>Sleepy<\/jats:italic> (<jats:italic>p\u2019s<\/jats:italic>&gt;0.05).\u00a0In conclusion, we found a lack of notable \u2018next day\u2019 impairment to cognitive and psychomotor function and simulated driving performance following evening use of 10 mg oral THC, in combination with 200 mg CBD, in an insomnia population who infrequently use cannabis.<\/jats:p>","DOI":"10.1007\/s00213-024-06595-9","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T08:01:40Z","timestamp":1715932900000},"page":"1815-1825","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evaluating possible \u2018next day\u2019 impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled trial"],"prefix":"10.1007","volume":"241","author":[{"given":"Anastasia","family":"Suraev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"McCartney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel S.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Vandrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald R.","family":"Grunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela L.","family":"D\u2019Rozario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delwyn","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla M.","family":"Hoyos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9307-7159","authenticated-orcid":false,"given":"Iain S.","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"6595_CR1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. https:\/\/doi.org\/10.1176\/appi.books.9780890425596","edition":"5"},{"issue":"9","key":"6595_CR2","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1007\/s00213-019-05246-8","volume":"236","author":"TR Arkell","year":"2019","unstructured":"Arkell TR, Lintzeris N, Kevin RC, Ramaekers JG, Vandrey R, Irwin C, Haber PS, McGregor IS (2019) Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology 236(9):2713\u20132724. https:\/\/doi.org\/10.1007\/s00213-019-05246-8","journal-title":"Psychopharmacology"},{"issue":"6","key":"6595_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.31128\/AJGP-02-21-5840","volume":"50","author":"TR Arkell","year":"2021","unstructured":"Arkell TR, McCartney D, McGregor IS (2021) Medical cannabis and driving. Aust J Gen Prac 50(6):357\u2013362. https:\/\/doi.org\/10.31128\/AJGP-02-21-5840","journal-title":"Aust J Gen Prac"},{"key":"6595_CR4","unstructured":"Australian Government Therapeutic Goods Administration. (2022) Medicinal cannabis products by active ingredients. https:\/\/www.tga.gov.au\/medicinal-cannabis-products-active-ingredients. Accessed 12 Jan 2024"},{"key":"6595_CR5","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3389\/fphar.2018.01521","volume":"9","author":"D Barchel","year":"2019","unstructured":"Barchel D, Stolar O, De-Haan T, Ziv-Baran T, Saban N, Fuchs DO, Koren G, Berkovitch M (2019) Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities. Front Pharmacol 9:1521. https:\/\/doi.org\/10.3389\/fphar.2018.01521","journal-title":"Front Pharmacol"},{"issue":"1","key":"6595_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/npp.2017.209","volume":"43","author":"DL Boggs","year":"2018","unstructured":"Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M (2018) Clinical and preclinical evidence for functional interactions of cannabidiol and \u03949-tetrahydrocannabinol. Neuropsychopharmacology 43(1):142\u2013154. https:\/\/doi.org\/10.1038\/npp.2017.209","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"6595_CR7","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1111\/j.1360-0443.2012.03928.x","volume":"107","author":"WM Bosker","year":"2012","unstructured":"Bosker WM, Kuypers KP, Theunissen EL, Surinx A, Blankespoor RJ, Skopp G, Jeffery WK, Walls HC, van Leeuwen CJ, Ramaekers JG (2012) Medicinal \u03949-tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests. Addiction 107(10):1837\u20131844. https:\/\/doi.org\/10.1111\/j.1360-0443.2012.03928.x","journal-title":"Addiction"},{"key":"6595_CR8","doi-asserted-by":"publisher","first-page":"107641","DOI":"10.1016\/j.drugalcdep.2019.107641","volume":"205","author":"B Brands","year":"2019","unstructured":"Brands B, Mann RE, Wickens CM, Sproule B, Stoduto G, Sayer GS, Burston J, Pan JF, Matheson J, Stefan C (2019) Acute and residual effects of smoked cannabis: Impact on driving speed and lateral control, heart rate, and self-reported drug effects. Drug Alcohol Depend 205:107641. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.107641","journal-title":"Drug Alcohol Depend"},{"key":"6595_CR9","doi-asserted-by":"crossref","unstructured":"Brookhuis KA, Volkerts ER, O\u2019Hanlon JF (1990) Repeated dose effects of lormetazepam and flurazepam upon driving performance. Eur J Clin Pharm 39:83\u201387\u00a0","DOI":"10.1007\/BF02657065"},{"issue":"21","key":"6595_CR10","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1001\/jama.2020.18544","volume":"324","author":"TB Cole","year":"2020","unstructured":"Cole TB, Saitz R (2020) Cannabis and impaired driving. JAMA 324(21):2163\u20132164. https:\/\/doi.org\/10.1001\/jama.2020.18544","journal-title":"JAMA"},{"issue":"1","key":"6595_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1089\/can.2017.0059","volume":"3","author":"B De Hoop","year":"2018","unstructured":"De Hoop B, Heerdink ER, Hazekamp A (2018) Medicinal cannabis on prescription in the Netherlands: statistics for 2003\u20132016. Cannabis Cannabinoid Res 3(1):54\u201355. https:\/\/doi.org\/10.1089\/can.2017.0059","journal-title":"Cannabis Cannabinoid Res"},{"issue":"4","key":"6595_CR12","doi-asserted-by":"publisher","first-page":"e2701","DOI":"10.1002\/hup.2701","volume":"34","author":"LE Devenney","year":"2019","unstructured":"Devenney LE, Coyle KB, Verster JC (2019) Memory and attention during an alcohol hangover. Hum Psychopharmacol Clin Experiment 34(4):e2701. https:\/\/doi.org\/10.1002\/hup.2701","journal-title":"Hum Psychopharmacol Clin Experiment"},{"key":"6595_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.sleep.2021.05.043","volume":"84","author":"MM Cruz","year":"2021","unstructured":"e Cruz MM, Kryger MH, Morin CM, Palombini L, Salles C, Gozal D (2021) Comorbid Insomnia and Sleep Apnea: Mechanisms and implications of an underrecognized and misinterpreted sleep disorder. Sleep Med 84:283\u2013288. https:\/\/doi.org\/10.1016\/j.sleep.2021.05.043","journal-title":"Sleep Med"},{"issue":"4","key":"6595_CR14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.20982\/tqmp.14.4.p242","volume":"14","author":"J-C Goulet-Pelletier","year":"2018","unstructured":"Goulet-Pelletier J-C, Cousineau D (2018) A review of effect sizes and their confidence intervals, Part I: The Cohen\u2019sd family. Quant Meth Psych 14(4):242\u2013265. https:\/\/doi.org\/10.20982\/tqmp.14.4.p242","journal-title":"Quant Meth Psych"},{"issue":"2","key":"6595_CR15","first-page":"93","volume":"23","author":"JR Grove","year":"1992","unstructured":"Grove JR, Prapavessis H (1992) Preliminary evidence for the reliability and validity of an abbreviated profile of mood states. Int J Sport Psychol 23(2):93\u2013109","journal-title":"Int J Sport Psychol"},{"issue":"7","key":"6595_CR16","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.braindev.2018.03.013","volume":"40","author":"M Hausman-Kedem","year":"2018","unstructured":"Hausman-Kedem M, Menascu S, Kramer U (2018) Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents\u2013An observational, longitudinal study. Brain Dev 40(7):544\u2013551. https:\/\/doi.org\/10.1016\/j.braindev.2018.03.013","journal-title":"Brain Dev"},{"issue":"3","key":"6595_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00213-022-06075-y","volume":"239","author":"K Iwamoto","year":"2022","unstructured":"Iwamoto K, Iwata M, Kambe D, Imadera Y, Tachibana N, Kajiyama Y, Ando M, Ozaki N (2022) Residual effects of zopiclone on driving performance using a standardized driving simulator among healthy volunteers. Psychopharmacology 239(3):841\u2013850. https:\/\/doi.org\/10.1007\/s00213-022-06075-y","journal-title":"Psychopharmacology"},{"key":"6595_CR18","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3389\/fpsyg.2013.00863","volume":"4","author":"D Lakens","year":"2013","unstructured":"Lakens D (2013) Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front Psychol 4:863. https:\/\/doi.org\/10.3389\/fpsyg.2013.00863","journal-title":"Front Psychol"},{"issue":"9","key":"6595_CR19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/08830738187730","volume":"33","author":"S Libzon","year":"2018","unstructured":"Libzon S, Schleider LB-L, Saban N, Levit L, Tamari Y, Linder I, Lerman-Sagie T, Blumkin L (2018) Medical cannabis for pediatric moderate to severe complex motor disorders. J Child Neurol 33(9):565\u2013571. https:\/\/doi.org\/10.1177\/08830738187730","journal-title":"J Child Neurol"},{"issue":"1","key":"6595_CR20","doi-asserted-by":"publisher","first-page":"e12870","DOI":"10.1111\/adb.12870","volume":"26","author":"NL Mason","year":"2021","unstructured":"Mason NL, Theunissen EL, Hutten NR, Tse DH, Toennes SW, Jansen JF, Stiers P, Ramaekers JG (2021) Reduced responsiveness of the reward system is associated with tolerance to cannabis impairment in chronic users. Addict Biol 26(1):e12870. https:\/\/doi.org\/10.1111\/adb.12870","journal-title":"Addict Biol"},{"key":"6595_CR21","doi-asserted-by":"publisher","first-page":"172937","DOI":"10.1016\/j.pbb.2020.172937","volume":"194","author":"J Matheson","year":"2020","unstructured":"Matheson J, Mann RE, Sproule B, Huestis MA, Wickens CM, Stoduto G, George TP, Rehm J, Le Foll B, Brands B (2020) Acute and residual mood and cognitive performance of young adults following smoked cannabis. Pharmacol Biochem Behav 194:172937","journal-title":"Pharmacol Biochem Behav"},{"key":"6595_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.pbb.2020.172937","volume":"126","author":"D McCartney","year":"2021","unstructured":"McCartney D, Arkell TR, Irwin C, McGregor IS (2021) Determining the magnitude and duration of acute \u03949-tetrahydrocannabinol (\u03949-THC)-induced driving and cognitive impairment: a systematic and meta-analytic review. Neurosci Biobehav Rev 126:175\u2013193. https:\/\/doi.org\/10.1016\/j.pbb.2020.172937","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"6595_CR23","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1089\/can.2022.0185","volume":"8","author":"D McCartney","year":"2022","unstructured":"McCartney D, Suraev A, McGregor IS (2022a) The \u201cnext day\u201d effects of cannabis use: a systematic review. Cannabis Cannabinoid Res 8(1):92\u2013114. https:\/\/doi.org\/10.1089\/can.2022.0185","journal-title":"Cannabis Cannabinoid Res"},{"key":"6595_CR24","doi-asserted-by":"publisher","unstructured":"McCartney D, Suraev AS, Doohan PT, Irwin C, Kevin RC, Grunstein RR, Hoyos CM, McGregor IS (2022b) Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial. J Psychopharmacol 36(12). https:\/\/doi.org\/10.1177\/02698811221095356","DOI":"10.1177\/02698811221095356"},{"issue":"5","key":"6595_CR25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ejvs.2018.02.028","volume":"55","author":"L Meuli","year":"2018","unstructured":"Meuli L, Dick F (2018) Understanding confounding in observational studies. Eur J Vasc Endovasc Surg 55(5):737. https:\/\/doi.org\/10.1016\/j.ejvs.2018.02.028","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"1","key":"6595_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/00325481.2020.1823724","volume":"133","author":"M Moline","year":"2021","unstructured":"Moline M, Zammit G, Yardley J, Pinner K, Kumar D, Perdomo C, Cheng JY (2021) Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials. Postgrad Med 133(1):71\u201381. https:\/\/doi.org\/10.1080\/00325481.2020.1823724","journal-title":"Postgrad Med"},{"issue":"S1","key":"6595_CR27","doi-asserted-by":"publisher","first-page":"121S","DOI":"10.1111\/j.1365-2125.1984.tb02590.x","volume":"18","author":"J O'Hanlon","year":"1984","unstructured":"O'Hanlon J (1984) Driving performance under the influence of drugs: rationale for, and application of, a new test. Br J Clin Pharmacol 18(S1):121S\u2013129S. https:\/\/doi.org\/10.1111\/j.1365-2125.1984.tb02590.x","journal-title":"Br J Clin Pharmacol"},{"issue":"S332","key":"6595_CR28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1600-0447.1986.tb08985.x","volume":"74","author":"JF O'Hanlon","year":"1986","unstructured":"O'Hanlon JF, Volkerts E (1986) Hypnotics and actual driving performance. Acta Psychiatr Scand 74(S332):95\u2013104. https:\/\/doi.org\/10.1111\/j.1600-0447.1986.tb08985.x","journal-title":"Acta Psychiatr Scand"},{"key":"6595_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/B978-0-323-89862-1.00027-1","volume-title":"Cannabis Use, Neurobiology, Psychology, and Treatment","author":"UW Preuss","year":"2023","unstructured":"Preuss UW, Hoch E, Wong J (2023) Cannabis, cognitive impairment and car crash risk. In: Cannabis Use, Neurobiology, Psychology, and Treatment. Elsevier Inc., pp 113\u2013124. https:\/\/doi.org\/10.1016\/B978-0-323-89862-1.00027-1"},{"key":"6595_CR30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.euroneuro.2020.01.006","volume":"36","author":"J Ramaekers","year":"2020","unstructured":"Ramaekers J, Mason N, Theunissen E (2020) Blunted highs: pharmacodynamic and behavioral models of cannabis tolerance. Eur Neuropsychopharmacol 36:191\u2013205. https:\/\/doi.org\/10.1016\/j.euroneuro.2020.01.006","journal-title":"Eur Neuropsychopharmacol"},{"issue":"14","key":"6595_CR31","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2018.1334","volume":"319","author":"JG Ramaekers","year":"2018","unstructured":"Ramaekers JG (2018) Driving under the influence of cannabis: an increasing public health concern. JAMA 319(14):1433\u20131434. https:\/\/doi.org\/10.1001\/jama.2018.1334","journal-title":"JAMA"},{"key":"6595_CR32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00213-010-2042-1","volume":"214","author":"JG Ramaekers","year":"2011","unstructured":"Ramaekers JG, Theunissen EL, De Brouwer M, Toennes SW, Moeller MR, Kauert G (2011) Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users. Psychopharmacology 214:391\u2013401. https:\/\/doi.org\/10.1007\/s00213-010-2042-1","journal-title":"Psychopharmacology"},{"key":"6595_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.aap.2018.11.011","volume":"123","author":"O Rogeberg","year":"2019","unstructured":"Rogeberg O (2019) A meta-analysis of the crash risk of cannabis-positive drivers in culpability studies\u2014avoiding interpretational bias. Accid Anal Prev 123:69\u201378. https:\/\/doi.org\/10.1016\/j.aap.2018.11.011","journal-title":"Accid Anal Prev"},{"issue":"8","key":"6595_CR34","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/add.13347","volume":"111","author":"O Rogeberg","year":"2016","unstructured":"Rogeberg O, Elvik R (2016) The effects of cannabis intoxication on motor vehicle collision revisited and revised. Addiction 111(8):1348\u20131359. https:\/\/doi.org\/10.1111\/add.13347","journal-title":"Addiction"},{"key":"6595_CR35","doi-asserted-by":"publisher","first-page":"107969","DOI":"10.1016\/j.drugalcdep.2020.107969","volume":"211","author":"NJ Schlienz","year":"2020","unstructured":"Schlienz NJ, Spindle TR, Cone EJ, Herrmann ES, Bigelow GE, Mitchell JM, Flegel R, LoDico C, Vandrey R (2020) Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis. Drug Alcohol Depend 211:107969. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.107969","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"6595_CR36","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00213-023-06356-0","volume":"240","author":"AM Schnakenberg Martin","year":"2023","unstructured":"Schnakenberg Martin AM, Flynn LT, Sefik E, Luddy C, Cortes-Briones J, Skosnik PD, Pittman B, Ranganathan M, D\u2019Souza DC (2023) Preliminary study of the interactive effects of THC and ethanol on self-reported ability and simulated driving, subjective effects, and cardiovascular responses. Psychopharmacology 240(6):1235\u20131246. https:\/\/doi.org\/10.1007\/s00213-023-06356-0","journal-title":"Psychopharmacology"},{"issue":"7","key":"6595_CR37","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/02698811211021583","volume":"35","author":"TR Spindle","year":"2021","unstructured":"Spindle TR, Martin EL, Grabenauer M, Woodward T, Milburn MA, Vandrey R (2021) Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis. J Psychopharmacol 35(7):786\u2013803. https:\/\/doi.org\/10.1177\/02698811211021583","journal-title":"J Psychopharmacol"},{"issue":"2","key":"6595_CR38","doi-asserted-by":"publisher","first-page":"e0149770","DOI":"10.1371\/journal.pone.0149770","volume":"11","author":"KE Sprecher","year":"2016","unstructured":"Sprecher KE, Riedner BA, Smith RF, Tononi G, Davidson RJ, Benca RM (2016) High resolution topography of age-related changes in non-rapid eye movement sleep electroencephalography. PLoS One 11(2):e0149770. https:\/\/doi.org\/10.1371\/journal.pone.0149770","journal-title":"PLoS One"},{"issue":"5","key":"6595_CR39","doi-asserted-by":"publisher","first-page":"e034421","DOI":"10.1136\/bmjopen-2019-034421","volume":"10","author":"A Suraev","year":"2020","unstructured":"Suraev A, Grunstein RR, Marshall NS, D'Rozario AL, Gordon CJ, Bartlett DJ, Wong K, Yee BJ, Vandrey R, Irwin C (2020) Cannabidiol (CBD) and \u03949-tetrahydrocannabinol (THC) for chronic insomnia disorder (\u2018CANSLEEP\u2019trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial. BMJ Open 10(5):e034421. https:\/\/doi.org\/10.1136\/bmjopen-2019-034421","journal-title":"BMJ Open"},{"key":"6595_CR40","doi-asserted-by":"publisher","first-page":"152188","DOI":"10.1016\/j.comppsych.2020.152188","volume":"102","author":"J Turna","year":"2020","unstructured":"Turna J, Balodis I, Munn C, Van Ameringen M, Busse J, MacKillop J (2020) Overlapping patterns of recreational and medical cannabis use in a large community sample of cannabis users. Compr Psychiatry 102:152188. https:\/\/doi.org\/10.1016\/j.comppsych.2020.152188","journal-title":"Compr Psychiatry"},{"key":"6595_CR41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.seizure.2016.01.004","volume":"35","author":"M Tzadok","year":"2016","unstructured":"Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, Nissenkorn A, Yosef OB, Hyman E, Granot D (2016) CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience. Seizure 35:41\u201344. https:\/\/doi.org\/10.1016\/j.seizure.2016.01.004","journal-title":"Seizure"},{"issue":"2","key":"6595_CR42","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/sleep\/25.2.224","volume":"25","author":"A Vermeeren","year":"2002","unstructured":"Vermeeren A, Riedel WJ, van Boxtel MP, Darwish M, Paty I, Patat A (2002) Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. Sleep 25(2):224\u2013231. https:\/\/doi.org\/10.1093\/sleep\/25.2.224","journal-title":"Sleep"},{"key":"6595_CR43","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1097\/00002826-198406001-00306","volume":"7","author":"E Volkerts","year":"1984","unstructured":"Volkerts E, Louwerens J, Gloerich A, Brookhuis K, O'hanlon, J. (1984) Zopiclone's residual effect upon actual driving performance versus those of nitrazepam and flunitrazepam. Clin Neuropharmacol 7:S337","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"6595_CR44","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/hup.470070502","volume":"7","author":"E Volkerts","year":"1992","unstructured":"Volkerts E, Van Laar M, Van Willigenburg A, Plomp T, Maes R (1992) A comparative study of on-the-road and simulated driving performance after nocturnal treatment with lormetazepam 1 mg and oxazepam 50 mg. Hum Psychopharmacol Clin 7(5):297\u2013309. https:\/\/doi.org\/10.1002\/hup.470070502","journal-title":"Hum Psychopharmacol Clin"},{"issue":"2","key":"6595_CR45","doi-asserted-by":"publisher","first-page":"e2254752","DOI":"10.1001\/jamanetworkopen.2022.54752","volume":"6","author":"CA Zamarripa","year":"2023","unstructured":"Zamarripa CA, Spindle TR, Surujunarain R, Weerts EM, Bansal S, Unadkat JD, Paine MF, Vandrey R (2023) Assessment of orally administered \u03949-tetrahydrocannabinol when coadministered with cannabidiol on \u03949-tetrahydrocannabinol pharmacokinetics and pharmacodynamics in healthy adults: A randomized clinical trial. JAMA Netw 6(2):e2254752. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.54752","journal-title":"JAMA Netw"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-024-06595-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-024-06595-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-024-06595-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T08:31:16Z","timestamp":1724401876000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-024-06595-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["6595"],"URL":"https:\/\/doi.org\/10.1007\/s00213-024-06595-9","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]},"assertion":[{"value":"15 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ISM is Academic Director\u00a0of\u00a0the Lambert Initiative for Cannabinoid Therapeutics, a philanthropically funded research program at the University\u00a0of\u00a0Sydney. He has served as an expert witness in various medicolegal cases involving cannabis and has received consulting fees from Medical Cannabis Industry Australia (MCIA) and Janssen.\u00a0He currently acts as an advisor\/consultant to Kinoxis Therapeutics, Psylo and Emyria. He reports research grants and salary support from the Australian National Health and Medical Research Council (NHMRC) and from Lambert\u00a0Initiative for Cannabinoid Therapeutics. He is an inventor on patents WO2018107216A1 and WO2017004674A1, licensed to Kinoxis Therapeutics involving use\u00a0of\u00a0novel small molecules (non-cannabinoid) to treat addictions and social deficits. ISM also has patents WO2020102857A1 and WO2021042178A1 related to use\u00a0of\u00a0small molecules (non-cannabinoid) for treating weight gain and opioid withdrawal, as well as patents WO2019227167 and WO2019071302 issued, which relate to cannabinoid therapeutics. CMH (GTN1104003) was supported by Dementia Research Development Fellowships of the Australian National Health and Medical Research Council-Australian Research Council (NHMRC-ARC) and by a National Heart Foundation Future Leader Fellowship. AS was supported by the Australian Government Research Training Program (RTP) and the Vice-Chancellor\u2019s Research Scholarship (VCRS) at the University of Sydney. AS has\u00a0received consulting fees from the Medical Cannabis Industry Australia (MCIA) and Haleon (consumer healthcare subsidiary of Glaxo Smith-Kline). RRG was supported by NHMRC Senior Principal Research and Investigator Fellowships (GTN1106974\/1197439) and has received a speaker fee from Eisai. ALD (NHMRC-ARC Dementia Research Development Fellowship GNT1107716 and NHMRC Emerging Leadership II Investigator Grant GNT2008001). RV has received compensation as a consultant or advisory board member for Jazz Pharmaceuticals, Mira1A Pharmaceuticals, Charlotte\u2019s Web, Canopy Health Innovations, WebMD, and Syqe Medical Ltd. All\u00a0other authors have no competing financial or non-financial\u00a0interests to declare.\u00a0The investigational product was purchased from BOD Australia who were not involved in the conception or design of this study, data analysis (with no access to the data) or the decision to publish. All other commercially available equipment was purchased.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}